Skip to main content
main-content
Top

06-27-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-treated type 2 diabetes

Author:
Eleanor McDermid

medwireNews: People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.

The improvements in glycated hemoglobin (HbA1c) were “robust and clinically meaningful,” said Dominik Dahl (Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, Germany), who presented the findings in a late-breaking poster session at the virtual ADA 81st Scientific Sessions.

The 475 people recruited to the trial were an average age of approximately 60 years, had type 2 diabetes lasting around 13 years, and were on a stable dose of insulin glargine but required a dose increase to achieve glycemic control.

During 40 weeks of follow-up, people randomly assigned to take placebo in addition to insulin achieved an average 0.93 percentage point reduction in HbA1c, from a baseline of 8.37% (68 mmol/mol). However, this necessitated an average 75.0% increase in their daily insulin dose, and they gained an average of 1.7 kg.

By contrast, people randomly assigned to take tirzepatide – a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide (GLP)-1 receptor agonist – achieved HbA1c reductions averaging 2.23, 2.59, and 2.59 percentage points with the 5, 10, and 15 mg/week doses, respectively. Average baseline HbA1c in the tirzepatide arms was 8.23–8.36% (66–68 mmol/mol).

Their insulin needs increased by an average of just 13.0% and 8.1% with the 5 and 10 mg/week doses, respectively, and decreased by 11.4% with the 15 mg/week dose. Moreover, their bodyweight fell by an average of 6.2, 8.2, and 10.9 kg with the three doses, respectively.

Decreased appetite was observed in approximately 7% to 14% of participants taking tirzepatide, compared with 1.7% of the placebo group, potentially contributing to weight loss.

The vast majority (93–97%) of participants in the tirzepatide groups achieved HbA1c levels lower than 7.0% (53 mmol/mol), compared with 34% of the placebo group, and 26–62% versus 3% achieved HbA1c with the nondiabetic range, below 5.7% (39 mmol/mol). Hypoglycemic events occurred at similar rates in all groups, including severe events.

Gastrointestinal events were the most common side effects, in line with the established safety profile of GLP-1 receptor agonists. But these predominantly occurred during the dose-escalation period, which lasted up to 20 weeks depending on the dose, and were infrequent during the rest of follow-up.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ADA Scientific Sessions; 25–29 June 2021

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

Related content

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity